Clinical Trial Update: Lenvatinib, Pembrolizumab, and Paclitaxel for Treatment of Recurrent Endometrial, Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer [Phase 2]

View source ↗

Summary

This Phase 2 trial is evaluating the combination of lenvatinib, pembrolizumab, and paclitaxel for recurrent endometrial, ovarian, fallopian tube, or primary per…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Endometrial Cancer
• Fallopian Tube Cancer
• Ovarian Cancer
• Peritoneal Cancer

Drugs mentioned

• KEYTRUDA (PEMBROLIZUMAB)
• LENVIMA (lenvatinib)
• PACLITAXEL (PACLITAXEL)

Snippet

Sponsor: Floor Backes, MD | Conditions: Platinum-Resistant Fallopian Tube Carcinoma, Platinum-Resistant Ovarian Carcinoma | Phase 2 | Status: ACTIVE_NOT_RECRUITING